Ibere Pharmaceuticals ^{Priced, NYSE: IBER.U}

We are a blank check company. Our sponsor is PIPV Capital LLC, a Delaware limited liability company. Our sponsor is led by Osagie Imasogie, Lisa Gray and Zoltan Kerekes, who are healthcare industry veterans who have worked together for the past two decades and initially managed GlaxoSmithKline Ventures, the intellectual property venture capital arm of GlaxoSmithKline PLC (LSE: GSK), where they executed approximately 30 transactions from 2000 to 2003. They subsequently formed Phoenix IP Ventures LLC ("PIPV"), which is a healthcare sector-focused private equity manager specializing in acquiring revenue-generating, high quality assets in the pharmaceutical and life sciences industries. PIPV has deployed in excess of $1 billion in institutional funds across diverse therapeutic areas, including dermatology, oncology, central nervous system, and analgesia/pain and over a broad, global scope. PIPV has generated returns exceeding 20%. Our acquisition strategy will leverage our management team’s proprietary network of long-standing relationships and industry contacts as well as inbound opportunities to source a business combination. We intend to identify and acquire one or more pharmaceutical or life science businesses.